
AbCellera Biologics (ABCL) P/E Ratio
P/E Ratio as of Jun 13, 2025: -5.64
Average-4.11
Median-3.68
Minimum-5.69
Maximum-3.47
-5.64
Past Month-2.03 (56.23%)
The P/E ratio for AbCellera Biologics (ABCL) is -5.64 as of Jun 13, 2025. This represents a increase of 20.26% compared to its 12-month average P/E ratio of -4.69. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
AbCellera Biologics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
AbCellera Biologics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing AbCellera Biologics to industry peers.
AbCellera Biologics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
AbCellera Biologics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing AbCellera Biologics to industry peers.
AbCellera Biologics (ABCL) P/E Ratio Insights
See AbCellera Biologics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in AbCellera Biologics (ABCL)
Order type
Buy in
Order amount
Est. shares
0 shares
AbCellera Biologics (ABCL) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $2.14 | -3.77 |
May 1, 2025 | $2.49 | -4.50 |
Apr 1, 2025 | $2.09 | -3.78 |
Mar 3, 2025 | $2.36 | -4.27 |
Feb 3, 2025 | $3.08 | -5.13 |
Jan 2, 2025 | $3.03 | -5.05 |
AbCellera Biologics (ABCL) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -5.64 | +15.57% |
2024 | -4.88 | -61.70% |
2023 | -12.74 | -210.02% |
2022 | 11.58 | -54.57% |
2021 | 25.49 | — |
FAQs About AbCellera Biologics (ABCL) P/E ratio
The latest P/E ratio of AbCellera Biologics (ABCL) is -5.64, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
AbCellera Biologics’s last 12-month average P/E ratio is -4.69, compared to its current P/E ratio of -5.64. This reflects a increase of 20.26%.
AbCellera Biologics’s current P/E ratio of -5.64 is higher than its last 12-month average P/E of -4.69. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
AbCellera Biologics’s average P/E ratio over the last 3 years is -5.21. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
AbCellera Biologics’s average P/E ratio over the last 5 years is 2.84. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.